Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient

Fuminori Teraishi; Kazuhide Ozaki; Yuichi Shibuya; Yasuo Shima; Toshio Nakamura; Madoka Hamada; Yasuo Fukui; Yutaka Nishioka; Tadashi Horimi; Yoshihiro Uchida

Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient

Fuminori Teraishi, Kazuhide Ozaki, Yuichi Shibuya, Yasuo Shima, Toshio Nakamura, Madoka Hamada, Yasuo Fukui, Yutaka Nishioka, Tadashi Horimi, Yoshihiro Uchida

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A 83-year-old man was admitted to our hospital for the treatment of advanced ascending colon cancer with liver metastases. He had initially undergone an ileocecal resection for ascending colon cancer. Subsequently, we started oral administration of UFT/LV (UFT 400 mg/day, LV 75 mg/day, and 4 weeks of therapy followed by a week suspension of treatment). After 3 courses, his tumors responded well to treatment, and CT showed marked regression of liver metastases. After 10 courses, liver metastases had almost disappeared. Two years passed without any adverse events since UFT/LV therapy was started. These findings suggest that UFT/LV therapy is very safe and effective for elderly patients with unresectable colorectal cancer.

Original language	English
Pages (from-to)	473-475
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	39
Issue number	3
Publication status	Published - Mar 2012
Externally published	Yes

Keywords

Colorectal cancer
Liver metastases
UFT/Leucovorin

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{cff8c5c0f9f74ac9b9f24ca12d9f8905,

title = "Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient",

abstract = "A 83-year-old man was admitted to our hospital for the treatment of advanced ascending colon cancer with liver metastases. He had initially undergone an ileocecal resection for ascending colon cancer. Subsequently, we started oral administration of UFT/LV (UFT 400 mg/day, LV 75 mg/day, and 4 weeks of therapy followed by a week suspension of treatment). After 3 courses, his tumors responded well to treatment, and CT showed marked regression of liver metastases. After 10 courses, liver metastases had almost disappeared. Two years passed without any adverse events since UFT/LV therapy was started. These findings suggest that UFT/LV therapy is very safe and effective for elderly patients with unresectable colorectal cancer.",

keywords = "Colorectal cancer, Liver metastases, UFT/Leucovorin",

author = "Fuminori Teraishi and Kazuhide Ozaki and Yuichi Shibuya and Yasuo Shima and Toshio Nakamura and Madoka Hamada and Yasuo Fukui and Yutaka Nishioka and Tadashi Horimi and Yoshihiro Uchida",

year = "2012",

month = mar,

language = "English",

volume = "39",

pages = "473--475",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "3",

}

TY - JOUR

T1 - Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient

AU - Teraishi, Fuminori

AU - Ozaki, Kazuhide

AU - Shibuya, Yuichi

AU - Shima, Yasuo

AU - Nakamura, Toshio

AU - Hamada, Madoka

AU - Fukui, Yasuo

AU - Nishioka, Yutaka

AU - Horimi, Tadashi

AU - Uchida, Yoshihiro

PY - 2012/3

Y1 - 2012/3

N2 - A 83-year-old man was admitted to our hospital for the treatment of advanced ascending colon cancer with liver metastases. He had initially undergone an ileocecal resection for ascending colon cancer. Subsequently, we started oral administration of UFT/LV (UFT 400 mg/day, LV 75 mg/day, and 4 weeks of therapy followed by a week suspension of treatment). After 3 courses, his tumors responded well to treatment, and CT showed marked regression of liver metastases. After 10 courses, liver metastases had almost disappeared. Two years passed without any adverse events since UFT/LV therapy was started. These findings suggest that UFT/LV therapy is very safe and effective for elderly patients with unresectable colorectal cancer.

AB - A 83-year-old man was admitted to our hospital for the treatment of advanced ascending colon cancer with liver metastases. He had initially undergone an ileocecal resection for ascending colon cancer. Subsequently, we started oral administration of UFT/LV (UFT 400 mg/day, LV 75 mg/day, and 4 weeks of therapy followed by a week suspension of treatment). After 3 courses, his tumors responded well to treatment, and CT showed marked regression of liver metastases. After 10 courses, liver metastases had almost disappeared. Two years passed without any adverse events since UFT/LV therapy was started. These findings suggest that UFT/LV therapy is very safe and effective for elderly patients with unresectable colorectal cancer.

KW - Colorectal cancer

KW - Liver metastases

KW - UFT/Leucovorin

UR - http://www.scopus.com/inward/record.url?scp=84861554492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861554492&partnerID=8YFLogxK

M3 - Article

C2 - 22421783

AN - SCOPUS:84861554492

VL - 39

SP - 473

EP - 475

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 3

ER -

Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this